Stockreport

GSK’s RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk

GSK plc American Depositary Shares (Each representing two Ordinary Shares)  (GSK) 
US:NYSE Investor Relations: gsk.com/en-gb/investors
PDF In the US, an estimated 21 million adults under 50 have at least one risk factor for severe RSV infection1* PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) tod [Read more]